Dibekacin derivatives and arbekacin derivatives active against resistant bacteria
US5488038A · kind A · utility
9Cited by
4References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 18, 1993 |
| Grant date | Jan 30, 1996 |
| Priority date | — |
| Expiry date | Nov 18, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H15/234
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
As new dibekacin derivatives and new arbekacin derivatives are now provided 2"-amino-2"-deoxydibekacin, 2"-amino-5,2"-dideoxydibekacin, 2"-amino-2"-deoxyarbekacin, 2"-amino-5,2"-dideoxyarbekacin, 2"-amino-5,2"-dideoxy-5-epi-fluoroarbekacin and 2"-amino-5,2"-dideoxy-5-epi-aminoarbekacin which all exhibit high antibacterial activity against a wide variety of gram-positive and gram-negative bacteria, including resistant bacteria such as methicillin-resistant Staphylococcus aureus and which are of low toxicity to mammals and are useful as antibacterial agent for treatment of bacterial infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.